| Biomarker ID | 632 |
| PMID | 21482022 |
| Year | 2011 |
| Biomarker | Base Model + %p2PSA |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 4.576 (95% CI: 2.540–8.243) |
| Effect on Pathways | Pathways include:-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Prostate Cancer Vs Controls |
| Type of Biomarker | Diagnostic |
| Cohort | 268 patients were chosen for the study out of which 107 suffered from prostate cancer. |
| Senstivity | 38.8% (95% CI: 22.4–43.2) |
| Specificity | 90% |
| AUC | 0.83 (95% CI: 0.78–0.89) |
| Accuracy | Base Model + 10% |
| Level Of Significance | p < 0.001 |
| Method Used | Access2 Immunoassay System analyzer |
| Clinical | No |
| Remarks | real clinical setting of consecutive men with tPSA 2.0–10 ng/ml and negative digital rectal examination were included. Base Model included all the variables that showed a corrected p value (pc)≤0.25 in comparisons between groups |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |